内克塔治疗 NKTR 深 沪
等待开盘 06-26 09:30:00 美东时间
62.155
-2.740
-4.22%
华盛通- 最 高67.96
- 今 开65.04
- 成交量 83.69万股
- 最 低 61.45
- 昨 收 64.895
- 总市值 1156.08万
- 52周最高 109.00
- 市盈率 静 --
- 换手率 449.92%
- 52周最低 21.02
- 委 比 -5.17%
- 总股本 0.00亿
- 历史最高 111.36
- 量 比 1.04
- 振 幅 10.03%
- 历史最低 0.35
- 每 手 1
- 风险率 18.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AEVEX Stock Is Surging Thursday: Post-IPO Momentum Explained
AEVEX Corp (NYSE:AVEX) shares are trading higher on Thursday as traders keep leaning into the post-IPO momentum in a high-volatility phase.
04-23 22:48
Nektar Therapeutics Launches $250M Common Stock Offering
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public
04-21 04:02
TD Cowen Initiates Coverage On Nektar Therapeutics with Buy Rating
TD Cowen analyst Marc Frahm initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating.
03-17 22:45
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Nektar Therapeutics -Announces $300M Public Offering
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
02-11 05:23
Where Nektar Therapeutics Stands With Analysts
In the preceding three months, 5 analysts have released ratings for Nektar Ther...
01-30 04:01
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.
2025-12-23 05:19
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.
2025-12-17 00:30
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Nektar治疗公司湿疹药物试验结果乐观 股价翻倍
Nektar表示，其 2b 期研究在 393 名中重度特应性皮炎患者中开展。 核心要点 美国生物科技公司Nektar治疗（Nektar Therapeutics）称其湿疹治疗药物的中期研究达到目标，该股周二早盘交易中股价翻倍。 这家生物科技公司表示，在全球范围内针对 393 名中重度特应性皮炎患者开展的 2b 期 REZOLVE-AD 研究显示，经过 16 周三次皮下注射 rezpegaldesleukin 治疗后，取得了成功结果。 Nektar首席执行官霍华德・W・罗宾（Howard W． Robin）表示，该研究表明 “调节性 T 细胞（Tregs）有望成为治疗炎症性皮肤疾病和其他自身...
2025-06-25 00:07
